Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).
暂无分享,去创建一个
J. Blay | F. Bertucci | A. Cesne | O. Mir | M. Toulmonde | A. Italiano | I. Ray-Coquard | O. Bouché | D. Pérol | N. Isambert | E. Bompas | F. Duffaud | P. Cassier | A. Adenis | M. Molimard | M. Ríos | J. Dômont | C. Cropet | J. Gautier | A. Belleville